Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences has outperformed the broader market over the past year, and analysts are moderately optimistic about the ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a ...

President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas, the White House said ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra’s AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement ...

Design software company Figma just went public in the hottest IPO of the year. Here's what its biggest investors' stakes are ...

President Donald Trump sent letters to 17 pharmaceutical CEOs demanding lower drug prices within 60 days, following an executive order signed earlier this year. According to the letter, the order is ...

In late June, the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), a group of independent experts ...

Pheton is just the latest example of wild trading moves seen in Chinese companies that trade on Nasdaq. Read more at straitstimes.com. Read more at straitstimes.com.